Huber, Jeffrey T.; Gillaspy, Mary L.
October 2000
Encyclopedic Dictionary of AIDS-Related Terminology;2000, p195
Reference Entry
An encyclopedia entry for saquinavir is presented. Saquinavir is the first protease inhibitor approved by the U.S. Food and Drug Administration. The drug was approved more quickly than any other new HIV drug at that time. Saquinavir is manufactured by Roche Laboratories, with the trade name Invirase.


Related Articles

  • New & improved.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p108 

    Reports that the US Food and Drug Administration has granted marketing clearance for Hoffman-La Roche's Fortovase (saquinavir), a soft gelatin formulation of the first available protease inhibitor. Indication of the drug.

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Nolan, David // Drug Safety;2005, Vol. 28 Issue 12, p1069 

    Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the...

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • Improved formulation of AIDS drug granted approval.  // Drug Store News;12/8/97, Vol. 19 Issue 20, pCP4 

    Reports the marketing approval granted to Hoffmann-LaRoche Inc. for the improved soft gelatin formulation of its protease inhibitor Invirase (saquinavir mesylate). Features of the product and its effectivity; Availability of Invirase.

  • Can the thymus win the battle against drug-resistant HIV? Haynes, Barton F.; Sempowski, Gregory D. // Nature Medicine;Jun2001, Vol. 7 Issue 6, p661 

    Focuses on the replication of protease inhibitors (PI) resistant HIV in the human thymus. Causes of PI resistance in the HIV protease gene; Effect of differences in signaling and cytokine production on the ability of PI-resistant HIV to replicate in thymocytes.

  • Fosamprenavir. Ellis, Jennifer M.; Ross, Jack W.; Coleman, Craig I. // Formulary;Mar2004, Vol. 39 Issue 3, p151 

    Fosamprenavir ( Lexiva, GlaxosSmithKline/Vertex) is the latest protease inhibitor (PI) approved by FDA for the treatment HIV-1 infection. A prodrug of amprenavir (APV), fosamprenavir has improved solubility and bioavailability over the parent PI, allowing for once-or twice-daily dosing and a...

  • lopinavir with ritonavir.  // Royal Society of Medicine: Medicines;2002, p340 

    The article presents information on the drug lopinavir with ritonavir. This drug is a combination of two protease inhibitors, lopinavir and ritonavir, available only in combination, and is used in the treatment of HIV infection. Administration is oral. Its side effects include dirrhoea, nausea...

  • DAD study: Use of protease inhibitors increases risk of myocardial infarction.  // Formulary;Aug2007, Vol. 42 Issue 8, p465 

    The article presents the clinical findings of Data Collection on Adverse Events of Anti-HIV Drugs (DAD) concerning the use of protease inhibitors in myocardial infarction (MI). The study reveals that the use of protease inhibitors increases the risk of MI. Among the patients investigated, 345...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics